Jane Kendrew joined Sygnature Discovery in June 2020 as Director of Translational Oncology.
Jane has over 29 years drug discovery experience in the area of oncology therapeutics and is a highly-experienced in vivo pharmacologist who has worked across a broad range of biology areas and phases of drug discovery. Her experience in applying in vivo pharmacology to drug discovery spans all phases from target validation to lead optimisation to support of clinical candidates.
Jane worked for AstraZeneca R&D Alderley Park for over 27 years and was responsible for leading the in vivo pharmacology group in the UK. She was instrumental in establishing and building the team in Cambridge and managed the in vivo pharmacology aspects of the portfolio of projects across the 2 sites within the UK. On leaving AZ, Jane established a highly successful in vivo pharmacology CRO, specialising in bespoke support to SME and academics and their drug discovery projects, applying her wealth of expertise and experience in drug discovery to novel areas of biology and therapeutic modalities.
She has a First Class BSc (Hons.) in Applied Biology and is an author on over 30 peer reviewed papers. During her career, she has significantly contributed to the success of a number of drugs within the AZ oncology portfolio.